All News

Arthritis%20Flare1.jpg

Despite Gout Numbers and Flares, Allopurinol is Underutilized

d Jack Cush, MD

A population-based survey from South Australia shows that gout flares are common in the community and have a significant effect on health-related quality of life (HRQoL), yet there is significant undertreatment of gout, even in those on current allopurinol.

Read Article
Echard.jpg

ACR Announces New Executive Vice President Steven Echard

d Jack Cush, MD

The American College of Rheumatology (ACR) Board of Directors is pleased to announce that Steven C. Echard, IOM, CAE  is the new Executive Vice President (EVP) of the American College of Rheumatology.

Read Article
RN.podcast.resized.jpg

RheumNow Podcast – Rituximab Monitoring (5.31.19)

d Jack Cush, MD

Dr. Jack Cush presents the news and best of rheumatology and medicine from the past week on RheumNow.com

Read Article
lupus_0.jpg

Lupus Disease Control with Rituximab

d RheumNow

Rituximab (Rituxan) may be an option for maintenance therapy in patients with difficult-to-treat systemic lupus erythematosus (SLE), European researchers reported.

Read Article
multitasking.jpg

The Cost of Physician Burnout

d Jack Cush, MD

An article in the Annals of Internal Medicine has analyzed the cost-consequences of physician burnout, including costs related to physician turnover and reduced clinical hours.

Read Article
List.jpg (keep)

2019 EULAR Guidelines on Antiphospholipid Syndrome Management

d Jack Cush, MD

A EULAR task force has reviewed the medical literature and developed evidence-based recommendations for the management of antiphospholipid syndrome (APS) in adults. They note that a high-risk antiphospholipid antibody (aPL) profile is associated with greater risk for thrombotic and obstetric APS.

Read Article
TNFinhib.jpg

Biologic Retention in Ankylosing Spondylitis Patients

d Jack Cush, MD

A study of biologic-naïve patients with ankylosing spondylitis (AS) who started therapy with a tumour necrosis factor inhibitor (TNFi) shows that after 5 years only 46% are still on a TNFi and that some are able to lower the dose over time.

Read Article
RheumNow is featuring "Therapeutic Update: Biosimilars in Rheumatology" with video insights from several experts, including Drs. Alvin Wells, Eric Ruderman, Vibeke Strand, Lee Simon and others. Sponsored by Sandoz, Inc.; available on RheumNow https://t.co/1vmnEJqOSi #sponsored

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is up! What to monitor with RTX therapy. Watch here> https://t.co/1aTy1axjXL or listen to the podcast on iTunes or SoundCloud>> https://t.co/fBY6O052NR

Links:

Dr. John Cush RheumNow ( View Tweet)

Prospective study of 4796 pts in the Osteoarthritis Initiative shows metformin use in obese pts (BMI>30) was Assoc with significantly less medial cartilage loss (0.71% vs. 1.57%/yr) & a trend towards fewer knee replacements over 6 yrs (OR 0.30, p = 0.11) https://t.co/LD0jFWtSLM

Links:

Dr. John Cush RheumNow ( View Tweet)

Japanese study 198 systemic sclerosis pts finds higher skin thickness scores (modified Rodnan Skin Scores; mRSS) associated with higher risk of interstitial lung disease (P < 0.05), restrictive LDz(P < 0.01), and diffusion impairment (P < 0.05) https://t.co/PY4n6N5Ub9

Links:

Dr. John Cush RheumNow ( View Tweet)

Korean National Health Insurance data compared the risk of CV events in 39,640 gout pts starting allopurinol or febuxostat. MACE incidence was 1.89 vs 1.84/100PY (HR 1.09; 0.90, 1.32) Thus, no significant difference in CV risk with these agents in Asians https://t.co/l316siAqd8

Links:

Dr. John Cush RheumNow ( View Tweet)

Alopecia areata pts have a higher risk of mortality assoc w/ self-harm, psychiatric dz (HR, 1.21) & smoking-associated malignant diseases including lung cancer (HR, 2.16), but not all cause mortality. Increases higher w/ Alopecia totalis/universalis. https://t.co/idVGmSTcRE

Links:

Dr. John Cush RheumNow ( View Tweet)

In a study of 678 first-degree relatives (FDRs) of RA patients and 330 osteoarthritis (OA) subjects, increasing age is associated with increasing positive results for the CCP3.1 and CCP-IgA test results - just like RF. https://t.co/0iwK0CjxUj

Links:

Dr. John Cush RheumNow ( View Tweet)

184 juvenile Fibromyalga pts randomized to PBO or duloxetine (30-->60mg/d) for 13wks. Those on duloxetine failed the primary endpoint - mean 24 hr change in Brief Pain Inventory (BPI), but more Cymbalt pts had 30% nd 50% BPI reductions https://t.co/EuyCRqKzN7

Links:

Dr. John Cush RheumNow ( View Tweet)

Japanese study 198 systemic sclerosis pts finds that higher skin thickness scores (modified Rodnan Skin Scores; mRSS) associated with higher risk of interstitial lung disease (P < 0.05), restrictive LDz(P < 0.01), and diffusion impairment (P < 0.05) https://t.co/PY4n6N5Ub9

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA is seeking public input into CBD - cannabidiol - and will be holding a public hearing on CBD this friday May 31st. https://t.co/00MYFNESQ3

Links:

Dr. John Cush RheumNow ( View Tweet)

Risk factors for gouty tophi that ulcerate include: glucocorticoid overuse, tophi duration, and the number of tophi. Based on a chinese study of 105 tophaceous patients of whom 33 developed ulcerations https://t.co/rzYTFCb5jk

Links:

Dr. John Cush RheumNow ( View Tweet)

Research by Robinson and colleagues at Stanford show that mast cell inhibition or depletion significantly improved osteoarthritis in a mouse model. Mast cell driven tryptase increases inflammation, chondrocyte apoptosis, and cartilage breakdown https://t.co/LpgZUhDHvQ

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr. Madelaine Feldman's outstanding lecture on Drug Costs in America: The Bad, the Worse and The Despicable, is available for free at RheumNow Live On Demand at https://t.co/1jGiIQXvua. Check it out - you'll be glad you did. #rheumed #rheum https://t.co/MuNzooK8YB

Links:

Dr. John Cush RheumNow ( View Tweet)
×